Company / Capital Expenditures
RAPT Therapeutics, Inc. Capital Expenditures History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$122.0K
FY2024
5-year range
$122.0K / $1.1M
FY2020-FY2024
Trend
-89.2%
vs FY2023
Sector context
#170 of 195
Health Care
What the data says
RAPT Therapeutics, Inc.'s capital expenditures of $122,000 is lower than 87% of companies in the Health Care sector (FY2024). Declined from $845,000 to $122,000 over the past 2 years.
Based on SEC 10-K filings.
$122,000 in FY2024 with a 5-year CAGR of -32.8%.
Declined from $845,000 to $122,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -45.5%
- 5-Year CAGR
- -32.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 195This company $122.0K Sector average $117.2M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -32.8%, indicating a declining trend.
- In FY2024, capital expenditures decreased 89.2% year-over-year.
- Ranks #170 out of 195 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $122.0K | -89.2% |
| FY2023 | $1.1M | +33.1% |
| FY2022 | $845.0K | +11.9% |
| FY2021 | $755.0K | +89.7% |
| FY2020 | $398.0K | -55.2% |
| FY2019 | $888.0K | -74.6% |
| FY2018 | $3.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026